Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma

Authors

  • Edwin R. Fisher M.D.,

    Corresponding author
    1. National Surgical Adjuvant Breast and Bowel Project Pathology Center and Allegheny General Hospital, West Penn Allegheny Health System, Pittsburgh, Pennsylvania
    • Allegheny General Hospital, Cancer Center, 5th Floor, 320 East North Avenue, Pittsburgh, PA 15212
    Search for more papers by this author
    • Fax: (412) 359-8685

  • Stewart Anderson Ph.D.,

    1. Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • Scott Dean M.B.A.,

    1. Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • David Dabbs M.D.,

    1. Department of Pathology, Magee-Womens Hospital, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • Bernard Fisher M.D.,

    1. National Surgical Adjuvant Breast and Bowel Project Operations Center and Allegheny General Hospital, West Penn Allegheny Health System, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • Richard Siderits M.D.,

    1. Department of Pathology, Robert Wood Johnson University Hospital, Hamilton, New Jersey
    Search for more papers by this author
  • Jeffrey Pritchard D.O.,

    1. National Surgical Adjuvant Breast and Bowel Project Pathology Center and Allegheny General Hospital, West Penn Allegheny Health System, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • Telma Pereira M.D.,

    1. National Surgical Adjuvant Breast and Bowel Project Pathology Center and Allegheny General Hospital, West Penn Allegheny Health System, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • Charles Geyer M.D.,

    1. National Surgical Adjuvant Breast and Bowel Project Operations Center and Allegheny General Hospital, West Penn Allegheny Health System, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • Norman Wolmark M.D.

    1. National Surgical Adjuvant Breast and Bowel Project Operations Center and Allegheny General Hospital, West Penn Allegheny Health System, Pittsburgh, Pennsylvania
    Search for more papers by this author

Abstract

BACKGROUND

The authors attempted to resolve the dilemma posed by the lack of unanimity concerning the optimal immunohistochemical (IHC) method for determining and scoring estrogen receptor (ER) and progesterone receptor (PR).

METHODS

Sections for IHC were prepared from paraffin embedded tumor samples from 402 patients with lymph node positive breast carcinoma who had biochemical receptor values (obtained with the dextran-coated charcoal [DCC] method) and who were enrolled in a prospective, randomized trial (National Surgical Adjuvant Breast and Bowel Project protocol B-09). IHC receptors were scored independently by two observers according to percent, intensity, and any-or-none algorithms. Results from these evaluations and from two computer-assisted evaluations, DCC, and common pathologic characteristics were analyzed for optimum splits for positive reactions in univariate and multivariate analyses using a tree-structured model. Concordance, sensitivity, and specificity were determined between the DCC method and all other methods.

RESULTS

Interobserver agreement and concordance between the DCC method and the other methods and among the methods were high. Univariate analyses revealed that a positive ER score obtained with all methods was related significantly to overall survival (OS) at 5 years and at 10 years. Results related to PR scores and disease-free survival and recurrence-free survival were less consistent. In multivariate analysis, it also was found that all methods for scoring ER predicted a better prognosis for OS in patients with an unfavorable lymph node status at 5 years and 10 years. Patients in a favorable lymph node status group were discriminated further by nuclear grade.

CONCLUSIONS

All IHC methods for scoring ER appeared valid as prognostic indicators of OS in patients with positive lymph nodes. The any-or-none IHC method, by virtue of its simplicity, represents an appropriate choice for practical use. Cancer 2005. © 2004 American Cancer Society.

Ancillary